Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Erlangen – page 9

390 clinical trials in Erlangen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erlangen at a glance
390
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

390 trials in Erlangen

Open in trial search

Acute myeloid leukaemia+2

Recruiting

Study on Ivosidenib for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome with IDH1 Mutation After Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Technische Universitat Dresden

Axial spondyloarthritis+1

Recruiting

Study on the Effects of Sonelokimab in Patients with Active Psoriatic Arthritis or Axial Spondyloarthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Ewing's sarcoma

Recruiting

Study on Dinutuximab Beta and Drug Combination for Children, Teens, and Adults with GD2-Positive Ewing Sarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

Still's disease+1

Recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bladder cancer

Recruiting

Study of EG-70 for Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG or High-Risk Patients New to BCG or with Incomplete BCG Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lauromacrogol 400
  • Sponsor:Engene Inc.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Breast cancer+1

Recruiting

A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Universitaetsklinikum Ulm AöR

Basal cell carcinoma

Recruiting

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Chronic graft versus host disease

Recruiting

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Colon cancer stage III+1

Recruiting

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

T-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Triple negative breast cancer

Recruiting

Study on NECVAX-NEO1 and Paclitaxel Albumin-Bound for Patients with Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Necvax-Neo1
  • Sponsor:NEC Bio Therapeutics GmbH

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Erlangen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of new therapies for HR-positive and HER2-negative variants. Additional research encompasses lung cancer and various lymphomas.

  • Advanced/Metastatic Breast Cancer Treatments
  • Non-small Cell Lung Cancer Therapy
  • Lymphoma Treatment Approaches

Studies evaluate novel therapeutic combinations and targeted treatments for improved patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, including lupus erythematosus, psoriasis, and systemic conditions. Studies focus on innovative therapeutic approaches.

  • Cutaneous Lupus Treatment
  • Plaque Psoriasis Management
  • Systemic Sclerosis Research

Trials aim to develop more effective treatments for chronic autoimmune conditions.

03 Neurological Disorders

Clinical investigations focusing on acute cerebral ischemic stroke and multiple system atrophy. Research emphasizes innovative therapeutic approaches for better patient outcomes.

  • Stroke Treatment Development
  • Multiple System Atrophy Management
  • Neurological Disease Interventions

Studies evaluate new therapeutic agents and treatment strategies for neurological conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.